An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Puma Biotechnology, Inc. (NASDAQ: PBYI) will host a conference call to discuss its first quarter 2024 financial results on May 2, 2024. The call will be accessible via phone or webcast, with a replay available on the company's website. Investors and analysts can participate to learn about the latest financial performance and strategic updates.
Puma Biotechnology, Inc. (NASDAQ: PBYI) organizzerà una conferenza telefonica per discutere i risultati finanziari del primo trimestre del 2024 il 2 maggio 2024. La conferenza sarà accessibile tramite telefono o webcast, con una registrazione disponibile sul sito web dell'azienda. Gli investitori e gli analisti possono partecipare per conoscere le ultime prestazioni finanziarie e gli aggiornamenti strategici.
Puma Biotechnology, Inc. (NASDAQ: PBYI) llevará a cabo una llamada de conferencia para discutir los resultados financieros del primer trimestre de 2024 el 2 de mayo de 2024. La llamada se podrá acceder por teléfono o transmisión web, con una repetición disponible en el sitio web de la empresa. Inversores y analistas pueden participar para conocer el último rendimiento financiero y las actualizaciones estratégicas.
Puma Biotechnology, Inc. (NASDAQ: PBYI)는 2024년도 1분기 재무 결과를 논의하기 위해 2024년 5월 2일에 컨퍼런스 콜을 개최할 예정입니다. 이 통화는 전화 또는 웹캐스트를 통해 접속할 수 있으며, 회사 웹사이트에서는 다시 들을 수 있는 서비스가 제공됩니다. 투자자들과 분석가들은 최신 재무 성과와 전략 업데이트에 대해 배울 수 있습니다.
Puma Biotechnology, Inc. (NASDAQ: PBYI) organisera une conférence téléphonique le 2 mai 2024 pour discuter des résultats financiers du premier trimestre de 2024. L'appel pourra être suivi par téléphone ou via webcast, avec une rediffusion disponible sur le site web de l'entreprise. Les investisseurs et les analystes peuvent participer pour apprendre sur les dernières performances financières et les mises à jour stratégiques.
Puma Biotechnology, Inc. (NASDAQ: PBYI) wird am 2. Mai 2024 eine Telefonkonferenz abhalten, um die Finanzergebnisse des ersten Quartals 2024 zu besprechen. Der Anruf ist über Telefon oder Webcast zugänglich, mit einer Wiederholung, die auf der Website des Unternehmens verfügbar ist. Investoren und Analysten können teilnehmen, um die neuesten finanziellen Leistungen und strategischen Updates zu erfahren.
Positive
None.
Negative
None.
LOS ANGELES--(BUSINESS WIRE)--
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 2, 2024, following the release of its first quarter 2024 financial results.
The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approximately one hour after completion of the call and will be archived on Puma’s website for 90 days.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.
In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer.
we focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.
